According to Nagata et al (2004), activation of PTEN in HER2/neu-amplified breast cancer could contribute to the efficacy of trastuzumab; it was also demonstrated that efficacy of trastuzumab in clinical samples of HER2/neu-amplified breast cancer is significantly associated with PTEN expression. This evidence concerns the gene ERBB2 and breast carcinoma.